Synopsis
Synopsis
0
JDMF
0
VMF
0
Australia
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
1. Estrone Sulfate
2. Estrone Sulfate, 14c-labeled
3. Estrone Sulfate, 16-(14)c-labeled
4. Estrone Sulfate, Ammonium Salt
5. Estrone Sulfate, Potassium Salt
6. Estrone Sulfate, Sodium Salt
7. Estrone-3-sulfate
8. Evex
9. Oestrone Sulphate
10. Potassium Estrone Sulfate
11. Sodium Estrone Sulfate
1. Sodium Estrone Sulfate
2. Estrone Sodium Sulfate
3. 438-67-5
4. Estrone Sodium Sulphate
5. Estrone 3-sulfate Sodium Salt
6. Conestoral
7. Hyhorin
8. Morestin
9. Estrone Sulfate Sodium
10. Par Estro
11. Estrone Sulfate Sodium Salt
12. Estrone-3-sulfate Sodium Salt
13. Sodium Estrone Sulphate
14. Sodium Estrone 3-sulfate
15. Oestrone-3-sulphate Sodium Salt
16. Estrogenic Substances (conjugated)
17. Estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, Sodium Salt
18. 6k6fda543a
19. Chebi:8389
20. 17-oxoestra-1,3,5(10)-trien-3-yl Sodium Sulfate
21. Nsc-18313
22. Estrone Sulfate (sodium)
23. Sodium;[(8r,9s,13s,14s)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-yl] Sulfate
24. Sodium Estrone-3-sulfate
25. 1,3,5(10)-estratrien-3-ol-17-one Sulphate, Sodium Salt
26. Smr000058772
27. Einecs 207-120-4
28. Nsc 18313
29. Unii-6k6fda543a
30. Conjugated Estrogens: Sodium Estrone Sulfate
31. Estrone3-sulfatesodiumsalt
32. Sodium (8r,9s,13s,14s)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6h-cyclopenta(a)phenanthren-3-yl Sulfate
33. Sodium (8r,9s,13s,14s)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6h-cyclopenta[a]phenanthren-3-yl Sulfate
34. Sodium 17-oxoestra-1(10),2,4-trien-3-yl Sulfate
35. Estrone, Hydrogen Sulfate, Sodium Salt
36. Schembl4616
37. Mls000069757
38. Mls001424259
39. Chembl2106240
40. Dtxsid00860005
41. Dtxsid70881181
42. Hms2052j05
43. Hms2232j23
44. Discontinued. See E889070
45. Akos015967195
46. Estrone Sodium Sulfate [vandf]
47. Ccg-101163
48. Hy-113293b
49. Nc00413
50. Estrone Sodium Sulfate [who-dd]
51. Cs-0108249
52. D00312
53. Q4118295
54. Sodium 17-oxoestra-1,3,5(10)-trien-3-yl Sulfate
55. Estrone 3-sulfate Sodium Salt, Stabilized With Tris
56. Estra-1,3,5(10)-trien-17-one 3-(sulfooxy) Sodium Salt
57. Sodium [(8r,9s,13s,14s)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-yl] Sulfate
Molecular Weight | 372.4 g/mol |
---|---|
Molecular Formula | C18H21NaO5S |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 2 |
Exact Mass | 372.10073922 g/mol |
Monoisotopic Mass | 372.10073922 g/mol |
Topological Polar Surface Area | 91.9 Ų |
Heavy Atom Count | 25 |
Formal Charge | 0 |
Complexity | 630 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Premarin |
PubMed Health | Conjugated Estrogens (By mouth) |
Drug Classes | Endocrine-Metabolic Agent, Musculoskeletal Agent |
Drug Label | Premarin Intravenous (conjugated estrogens, USP) for injection contains a mixture of conjugated estrogens obtained exclusively from natural sources, occurring as the sodium salts of water-soluble estrogen sulfates blended to represent the average com... |
Active Ingredient | Estrogens, conjugated |
Dosage Form | Tablet; Cream; Injectable |
Route | oral; Injection; Oral; Topical, vaginal |
Strength | 25mg/vial; 0.45mg; 1.25mg; 0.625mg/gm; 0.625mg; 0.9mg; 0.3mg |
Market Status | Prescription |
Company | Wyeth Pharms |
2 of 2 | |
---|---|
Drug Name | Premarin |
PubMed Health | Conjugated Estrogens (By mouth) |
Drug Classes | Endocrine-Metabolic Agent, Musculoskeletal Agent |
Drug Label | Premarin Intravenous (conjugated estrogens, USP) for injection contains a mixture of conjugated estrogens obtained exclusively from natural sources, occurring as the sodium salts of water-soluble estrogen sulfates blended to represent the average com... |
Active Ingredient | Estrogens, conjugated |
Dosage Form | Tablet; Cream; Injectable |
Route | oral; Injection; Oral; Topical, vaginal |
Strength | 25mg/vial; 0.45mg; 1.25mg; 0.625mg/gm; 0.625mg; 0.9mg; 0.3mg |
Market Status | Prescription |
Company | Wyeth Pharms |
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Estrogens conjugated manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Estrogens conjugated, including repackagers and relabelers. The FDA regulates Estrogens conjugated manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Estrogens conjugated API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Estrogens conjugated manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Estrogens conjugated supplier is an individual or a company that provides Estrogens conjugated active pharmaceutical ingredient (API) or Estrogens conjugated finished formulations upon request. The Estrogens conjugated suppliers may include Estrogens conjugated API manufacturers, exporters, distributors and traders.
click here to find a list of Estrogens conjugated suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Estrogens conjugated DMF (Drug Master File) is a document detailing the whole manufacturing process of Estrogens conjugated active pharmaceutical ingredient (API) in detail. Different forms of Estrogens conjugated DMFs exist exist since differing nations have different regulations, such as Estrogens conjugated USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Estrogens conjugated DMF submitted to regulatory agencies in the US is known as a USDMF. Estrogens conjugated USDMF includes data on Estrogens conjugated's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Estrogens conjugated USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Estrogens conjugated suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Estrogens conjugated Drug Master File in Korea (Estrogens conjugated KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Estrogens conjugated. The MFDS reviews the Estrogens conjugated KDMF as part of the drug registration process and uses the information provided in the Estrogens conjugated KDMF to evaluate the safety and efficacy of the drug.
After submitting a Estrogens conjugated KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Estrogens conjugated API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Estrogens conjugated suppliers with KDMF on PharmaCompass.
A Estrogens conjugated CEP of the European Pharmacopoeia monograph is often referred to as a Estrogens conjugated Certificate of Suitability (COS). The purpose of a Estrogens conjugated CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Estrogens conjugated EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Estrogens conjugated to their clients by showing that a Estrogens conjugated CEP has been issued for it. The manufacturer submits a Estrogens conjugated CEP (COS) as part of the market authorization procedure, and it takes on the role of a Estrogens conjugated CEP holder for the record. Additionally, the data presented in the Estrogens conjugated CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Estrogens conjugated DMF.
A Estrogens conjugated CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Estrogens conjugated CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Estrogens conjugated suppliers with CEP (COS) on PharmaCompass.
A Estrogens conjugated written confirmation (Estrogens conjugated WC) is an official document issued by a regulatory agency to a Estrogens conjugated manufacturer, verifying that the manufacturing facility of a Estrogens conjugated active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Estrogens conjugated APIs or Estrogens conjugated finished pharmaceutical products to another nation, regulatory agencies frequently require a Estrogens conjugated WC (written confirmation) as part of the regulatory process.
click here to find a list of Estrogens conjugated suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Estrogens conjugated as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Estrogens conjugated API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Estrogens conjugated as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Estrogens conjugated and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Estrogens conjugated NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Estrogens conjugated suppliers with NDC on PharmaCompass.
Estrogens conjugated Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Estrogens conjugated GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Estrogens conjugated GMP manufacturer or Estrogens conjugated GMP API supplier for your needs.
A Estrogens conjugated CoA (Certificate of Analysis) is a formal document that attests to Estrogens conjugated's compliance with Estrogens conjugated specifications and serves as a tool for batch-level quality control.
Estrogens conjugated CoA mostly includes findings from lab analyses of a specific batch. For each Estrogens conjugated CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Estrogens conjugated may be tested according to a variety of international standards, such as European Pharmacopoeia (Estrogens conjugated EP), Estrogens conjugated JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Estrogens conjugated USP).
LOOKING FOR A SUPPLIER?